image credit- shutterstock
Japan's Lotte Holdings has announced an investment in ClearideBio Therapeutics AG, an early-stage biotechnology startup pioneering next-generation antibody-drug conjugates (ADCs) for the treatment of solid tumours.
Founded in December 2025 and headquartered in Basel, Switzerland, ClearideBio is a preclinical-stage company building a rapidly expanding pipeline of ADC programmes designed to address critically unmet medical needs in oncology.
ClearideBio is currently advancing its lead preclinical ADC programme toward initial clinical development, while continuing to expand its broader pipeline of next-generation ADC assets targeting multiple solid tumour indications. The company’s near-term development strategy is focused on progressing preclinical programmes through key value-inflection milestones, with the goal of entering first-in-human studies in the coming years.
This investment marks Lotte’s first investment in a European biotechnology company and reflects its deep commitment to supporting innovative biotechnology startups globally at the earliest stages of their development. Lotte participated as lead investor in ClearideBio’s pre-seed financing round, underscoring its strong conviction in the company’s rigorous scientific approach, exceptional management team, and compelling long-term potential.
